SG11201408652SA - Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies - Google Patents
Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesInfo
- Publication number
- SG11201408652SA SG11201408652SA SG11201408652SA SG11201408652SA SG11201408652SA SG 11201408652S A SG11201408652S A SG 11201408652SA SG 11201408652S A SG11201408652S A SG 11201408652SA SG 11201408652S A SG11201408652S A SG 11201408652SA SG 11201408652S A SG11201408652S A SG 11201408652SA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- international
- immune response
- selection
- yeast
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 230000028993 immune response Effects 0.000 title abstract 5
- 238000002560 therapeutic procedure Methods 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 4
- 230000008901 benefit Effects 0.000 abstract 3
- 238000009169 immunotherapy Methods 0.000 abstract 3
- 238000011319 anticancer therapy Methods 0.000 abstract 2
- 238000001228 spectrum Methods 0.000 abstract 2
- 229920004482 WACKER® Polymers 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 230000003595 spectral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0036—Step by step routines describing the handling of the data generated during a measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/003853 A1 (51) International Patent Classification: G01N33/68 (2006.01) G01N33/574 (2006.01) (21) International Application Number: (74) Agent: HILLMAN, Lisa, M., W.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chica go, IL 60606 (US). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 61/664,329 61/664,308 26 June 2012 (26.06.2012) 26 June 2012 (26.06.2012) (71) Applicants (for all designated States except US): BIODESIX, INC. [US/US]; 2970 Wilderness Place, Suite 100, Boulder, CO 80301 (US). GLOBEIMMUNE, INC. [US/US]; 1450 Infinite Drive, Louisville, CO 80027 (US). (72) Inventors; and (71) Applicants (for US only)-. RODER, Joanna [GB/US]; 22105 W. Whitewood Drive, Steamboat Springs, CO 80487 (US). RODER, Heinrich [DE/US]; 22105 W. Whitewood Drive, Steamboat Springs, CO 80487 (US). PCT/US2013/032024 (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 15 March 2013 (15.03.2013) English English US US (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, [Continued on next page] (54) Title: MASS-SPECTRAL METHOD FOR SELECTION, AND DE-SELECTION, OF CANCER PATIENTS FOR TREAT MENT WITH IMMUNE RESPONSE GENERATING THERAPIES Fig. 11 oo m o o o CJ O & (57) Abstract: A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from admin istration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, alone or in com bination with another anti-cancer therapy. The method uses mass spectro metry of blood-derived a patient sample and a computer configured as a clas sifier using a naming set of class-labeled spectra from other cancer patients that either benefitted or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy. Also dis - closed are methods of treatment of a cancer patient, comprising administer ing yeast-based immune response generating therapy, which may a be yeast- based immunotherapy for mutated Ras-based cancer, to a patient selected by a test in accordance with predictive mass spectral methods disclosed herein, in which the class label for the spectra indicates the patient likely is to bene - fit from the yeast-based immunotherapy. WO 2014/003853 Al III llll IIII III III Hill III III III Hill II llll lllll llll 111 mill llll 111 llll TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, , , , . t , nn y , ML, MR, NE, SN, TD, TG). ~ wrth amended clarms (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261664329P | 2012-06-26 | 2012-06-26 | |
US201261664308P | 2012-06-26 | 2012-06-26 | |
PCT/US2013/032024 WO2014003853A1 (en) | 2012-06-26 | 2013-03-15 | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408652SA true SG11201408652SA (en) | 2015-01-29 |
Family
ID=48045749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408652SA SG11201408652SA (en) | 2012-06-26 | 2013-03-15 | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
Country Status (13)
Country | Link |
---|---|
US (2) | US9653272B2 (en) |
EP (1) | EP2864792A1 (en) |
JP (1) | JP6355630B2 (en) |
KR (1) | KR102103319B1 (en) |
CN (1) | CN104685360B (en) |
AU (1) | AU2013281221B2 (en) |
CA (1) | CA2878044C (en) |
HK (1) | HK1209835A1 (en) |
IL (1) | IL236266A0 (en) |
MX (1) | MX365418B (en) |
SG (1) | SG11201408652SA (en) |
TW (1) | TWI639001B (en) |
WO (1) | WO2014003853A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104685360B (en) | 2012-06-26 | 2018-02-13 | 比奥德希克斯股份有限公司 | The mass spectrometry method of the cancer patient treated for the therapy for selecting and going selection generation immune response |
US10037874B2 (en) | 2014-12-03 | 2018-07-31 | Biodesix, Inc. | Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry |
US11594403B1 (en) | 2014-12-03 | 2023-02-28 | Biodesix Inc. | Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample |
EP3242940B1 (en) | 2015-01-09 | 2023-03-29 | Etubics Corporation | Methods and compositions for combination immunotherapy |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
US10713590B2 (en) * | 2015-04-30 | 2020-07-14 | Biodesix, Inc. | Bagged filtering method for selection and deselection of features for classification |
EP3779998A1 (en) | 2015-07-13 | 2021-02-17 | Biodesix, Inc. | Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
RU2018127709A (en) * | 2016-01-22 | 2020-02-25 | Отрэйсис, Инк. | SYSTEMS AND METHODS FOR IMPROVING DIAGNOSTICS OF DISEASES |
US11710539B2 (en) | 2016-02-01 | 2023-07-25 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy |
US11232940B2 (en) * | 2016-08-02 | 2022-01-25 | Virgin Instruments Corporation | Method and apparatus for surgical monitoring using MALDI-TOF mass spectrometry |
CN116884477A (en) * | 2017-01-05 | 2023-10-13 | 佰欧迪塞克斯公司 | Methods for identifying cancer patients in a subset of overall poor prognosis that permanently benefit from immunotherapy |
JP2021502217A (en) * | 2017-11-09 | 2021-01-28 | モンテフィオーレ メディカル センターMontefiore Medical Center | Low-energy immune stimuli to treat cancer and metastases |
JP2021508104A (en) | 2017-12-15 | 2021-02-25 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use. |
US20210118538A1 (en) * | 2018-03-29 | 2021-04-22 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
CN113711313A (en) * | 2019-02-15 | 2021-11-26 | 佰欧迪塞克斯公司 | Predictive test for identifying early-stage NSCLC patients at high risk of relapse after surgery |
CN110674947B (en) * | 2019-09-02 | 2021-02-19 | 三峡大学 | Spectral feature variable selection and optimization method based on Stacking integrated framework |
CN112164448B (en) * | 2020-09-25 | 2021-06-22 | 上海市胸科医院 | Training method, prediction system, method and medium of immunotherapy efficacy prediction model |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2486400B1 (en) | 1980-07-09 | 1986-05-30 | Univablot | MEDICINAL PRODUCTS BASED ON YEAST OR THEIR INSOLUBLE EXTRACTS |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
JPS61219387A (en) * | 1985-03-27 | 1986-09-29 | Suntory Ltd | Novel yeast plasmid and transformation thereof |
US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
NZ271774A (en) | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5747282A (en) | 1994-08-12 | 1998-05-05 | Myraid Genetics, Inc. | 17Q-linked breast and ovarian cancer susceptibility gene |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
US20070048860A1 (en) | 1997-10-10 | 2007-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Carcinoembryonic antigen (CEA) peptides |
US20010055589A1 (en) | 1998-06-17 | 2001-12-27 | University Of Connecticut | Cancer immunotherapy improved by prior radiotherapy |
US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
CA2403292C (en) | 2000-04-06 | 2011-02-08 | Panacea Pharmaceuticals, Llc | Microbial delivery system |
US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
WO2002076499A2 (en) | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
KR20140067141A (en) | 2002-12-16 | 2014-06-03 | 글로브이뮨 | Yeast-based vaccines as immunotherapy |
US8135136B2 (en) | 2004-09-06 | 2012-03-13 | Koninklijke Philips Electronics N.V. | Audio signal enhancement |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
KR101294470B1 (en) | 2005-07-08 | 2013-08-07 | 가부시키가이샤 니콘 | Solid-state imaging element |
BRPI0613025A2 (en) | 2005-07-11 | 2010-12-14 | Globeimmune Inc | composition for reducing resistance to an agent, method for preparing a yeast vehicle and use of the composition |
US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
JP5198290B2 (en) | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | Yeast-based vaccines that induce immune responses |
BRPI0709340A2 (en) * | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutations and compositions and methods of use thereof |
US8024282B2 (en) | 2006-03-31 | 2011-09-20 | Biodesix, Inc. | Method for reliable classification of samples in clinical diagnostics using an improved method of classification |
US7867775B2 (en) | 2006-03-31 | 2011-01-11 | Biodesix, Inc. | Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway |
US7858389B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway |
US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
US7858390B2 (en) | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
US7906342B2 (en) | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
WO2008085024A1 (en) * | 2007-01-12 | 2008-07-17 | Erasmus University Medical Center Rotterdam | Identification and detection of peptides relating to specific disorders |
WO2008097863A2 (en) | 2007-02-02 | 2008-08-14 | Globeimmune, Inc. | Methods for producing yeast-based vaccines |
US8501167B2 (en) | 2007-03-19 | 2013-08-06 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
CA2727559A1 (en) | 2008-06-11 | 2009-12-17 | Nils Aage Brunner | Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
WO2010080804A1 (en) * | 2009-01-06 | 2010-07-15 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
EP3320915A1 (en) | 2009-04-17 | 2018-05-16 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
JP2011001315A (en) | 2009-06-19 | 2011-01-06 | Cellex Corp | Immunotherapy agent for pancreatic cancer |
CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
US20110208433A1 (en) * | 2010-02-24 | 2011-08-25 | Biodesix, Inc. | Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples |
US20130121964A1 (en) | 2010-03-14 | 2013-05-16 | Globeimmune, Inc. | Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy |
WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
ES2696551T3 (en) | 2010-12-17 | 2019-01-16 | Globeimmune Inc | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
US8914238B2 (en) | 2011-01-28 | 2014-12-16 | Biodesix, Inc. | Method for predicting breast cancer patient response to endocrine therapy |
PE20140844A1 (en) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | YEAST-BASED THERAPEUTICS FOR CHRONIC HEPATITIS B INFECTION |
EP2685995B1 (en) | 2011-03-17 | 2017-05-03 | Globeimmune, Inc. | Yeast-brachyury immunotherapeutic compositions |
SG195383A1 (en) | 2011-06-14 | 2013-12-30 | Globeimmune Inc | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
JP6122007B2 (en) | 2011-08-17 | 2017-04-26 | グローブイミューン,インコーポレイテッド | Yeast-MUC1 immunotherapy composition and use thereof |
WO2013093644A2 (en) | 2011-11-23 | 2013-06-27 | Uti Limited Partnership | Expression signature for staging and prognosis of prostate, breast and leukemia cancers |
EP2836836A1 (en) | 2012-04-13 | 2015-02-18 | Erasmus University Medical Center Rotterdam | Biomarkers for triple negative breast cancer |
CA2874989A1 (en) * | 2012-05-29 | 2013-12-05 | Biodesix, Inc. | Deep-maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof |
CN104685360B (en) | 2012-06-26 | 2018-02-13 | 比奥德希克斯股份有限公司 | The mass spectrometry method of the cancer patient treated for the therapy for selecting and going selection generation immune response |
EP3584642B1 (en) | 2018-06-18 | 2021-01-13 | Montres Breguet S.A. | Setting mechanism for watch display mechanism comprising a rotating drum. |
-
2013
- 2013-03-15 CN CN201380043182.4A patent/CN104685360B/en active Active
- 2013-03-15 US US13/835,909 patent/US9653272B2/en active Active
- 2013-03-15 KR KR1020157001998A patent/KR102103319B1/en active IP Right Grant
- 2013-03-15 CA CA2878044A patent/CA2878044C/en active Active
- 2013-03-15 MX MX2014015665A patent/MX365418B/en active IP Right Grant
- 2013-03-15 EP EP13714124.8A patent/EP2864792A1/en not_active Withdrawn
- 2013-03-15 JP JP2015520167A patent/JP6355630B2/en active Active
- 2013-03-15 WO PCT/US2013/032024 patent/WO2014003853A1/en active Application Filing
- 2013-03-15 SG SG11201408652SA patent/SG11201408652SA/en unknown
- 2013-03-15 AU AU2013281221A patent/AU2013281221B2/en active Active
- 2013-05-03 TW TW102115975A patent/TWI639001B/en active
-
2014
- 2014-12-15 IL IL236266A patent/IL236266A0/en unknown
-
2015
- 2015-10-26 HK HK15110515.8A patent/HK1209835A1/en unknown
-
2017
- 2017-05-02 US US15/584,275 patent/US10593529B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR102103319B1 (en) | 2020-04-22 |
US20170271136A1 (en) | 2017-09-21 |
US20130344111A1 (en) | 2013-12-26 |
KR20150023881A (en) | 2015-03-05 |
CA2878044C (en) | 2021-10-26 |
WO2014003853A1 (en) | 2014-01-03 |
TW201400812A (en) | 2014-01-01 |
CN104685360B (en) | 2018-02-13 |
AU2013281221A1 (en) | 2015-02-12 |
JP2015528110A (en) | 2015-09-24 |
US9653272B2 (en) | 2017-05-16 |
MX365418B (en) | 2019-06-03 |
MX2014015665A (en) | 2015-06-17 |
US10593529B2 (en) | 2020-03-17 |
CA2878044A1 (en) | 2014-01-03 |
HK1209835A1 (en) | 2016-04-08 |
JP6355630B2 (en) | 2018-07-11 |
CN104685360A (en) | 2015-06-03 |
IL236266A0 (en) | 2015-02-26 |
TWI639001B (en) | 2018-10-21 |
AU2013281221B2 (en) | 2018-05-17 |
EP2864792A1 (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408652SA (en) | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201807188VA (en) | Modified cells for immunotherapy | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production |